• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial

by MM360 Staff | Nov 25, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

New ‘powerful’ lab test will help researchers explore blood cancer

by Marisa Wexler, MS | Nov 24, 2025 | Myeloma News

Mission Bio has debuted a new laboratory test that enables researchers to simultaneously detect alterations in the genetic code and changes in genetic activity — starting with whether a gene is turned on or off — within the same cell. The test, dubbed the Tapestri...

Assessing the correlation between patient and family reported outcome measures and multiple myeloma clinical parameters

by MM360 Staff | Nov 24, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance

by MM360 Staff | Nov 22, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Case: Growth on pancreas shows estrogen link to pancreatic cancer

by Marisa Wexler, MS | Nov 21, 2025 | Myeloma News

Changes in how cells respond to the hormone estrogen may underlie the development of certain forms of pancreatic cancer. That’s according to findings from testing done on a growth removed from the pancreas of a woman in Japan who had given birth several months before....

Glioma trial of intranasal therapy NEO100 fills all patient slots

by Marisa Wexler, MS | Nov 20, 2025 | Myeloma News

Neonc Technologies has completed enrollment for its Phase 2a clinical trial of NEO100, an intranasal treatment for high-grade glioma, the company announced. This follows the release of positive interim data suggesting the experimental treatment, which uses a compound...
« Older Entries
Next Entries »

Recent Content

  • Reduced-versus Standard-dose Melphalan as Single-agent Conditioning Regimen in Auto HSCT for Multiple Myeloma: A Systematic Review and Meta-Analysis
  • Dosing begins in trial testing Enhertu for ovarian cancer
  • (no title)
  • (no title)
  • Teclistamab combo improves relapsed, refractory myeloma outcomes
  • Safety and Efficacy of Anti-B-cell Maturation Antigen (Anti-BCMA) Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma: A Systematic Review of Clinical Trials
  • (no title)
  • (no title)
  • CLN-049 now has FDA fast track designation for hard-to-treat AML
  • Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT